Nitroglycerin (Sublingual tablet): Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Nitroglycerin}} | {{Nitroglycerin}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{PB}} | ||
'''''For patient information, click <u>[[Nitroglycerin tablet (patient information)|here]]'''''</u>. | '''''For patient information, click <u>[[Nitroglycerin tablet (patient information)|here]]'''''</u>. | ||
Revision as of 21:44, 10 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
For patient information, click here.
Overview
Category
US Brand Names
FDA Package Insert
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
References
- ↑ "NITROSTAT (NITROGLYCERIN) TABLET [PARKE-DAVIS DIV OF PFIZER INC]". Retrieved 31 January 2014.